GlaxoSmithKline: Parkinson Disease trials
The registry lists 18 Parkinson Disease studies with GlaxoSmithKline as lead sponsor. 0 are open to participants now and 10 have results posted.
Phase 1 3Phase 2 2Phase 3 9Phase 4 3No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Evaluate the Efficacy of 18 to 24mg/Day Ropinirole Controlled Release (CR) Tablets in Early and Advanced Parkinson's Disease (PD) Patients.TerminatedNCT01929317Phase 3Results posted
- Open-Label Extension Study With REQUIP PR for Subjects From Study ROP111528CompletedNCT01536574Phase 3Results posted
- A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's DiseaseCompletedNCT01494532Phase 4Results posted
- A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's DiseaseCompletedNCT01485172Phase 4Results posted
- A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-DopaCompletedNCT01154166Phase 3Results posted
- Clinical Evaluation of Ropinirole Prolonged Release/Extended Release (PR/XR) Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's DiseaseCompletedNCT00823836Phase 3Results posted
- Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164CompletedNCT00650104Phase 3Results posted
- An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s DiseaseCompletedNCT00632736Phase 3Results posted
- REQUIP (Ropinirole Hydrochloride) IR Long-Term Phase 4 StudyCompletedNCT00485069Phase 4Results posted
- Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's Disease (PD)CompletedNCT00434304Phase 2Results posted
- Cardiovascular Events in Parkinson's Disease PatientsCompletedNCT01545856
- Ropinirole PR Pharmacokinetics Study Among Chinese Healthy SubjectsCompletedNCT01435915Phase 1
- LRRK2 Mutation and Parkinson's DiseaseTerminatedNCT01424475Phase 1
- A Study Conducted in Healthy Subjects to Demonstrate Bioequivalence Between Ropinirole Prolonged Release Tablets Manufactured at Crawley and ArandaCompletedNCT01371682Phase 1
- Parkinson's Disease Patient Study On Absorption, Distribution, Metabolism And Excretion Of RopiniroleCompletedNCT00460148Phase 2
- Investigational Parkinson's Disease In Patients Not Well Controlled On L-dopaCompletedNCT00381472Phase 3
- Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson'sCompletedNCT00363727Phase 3
- A Comparison of Ropinirole Immediate Release With Ropinirole Prolonged Release in Patients With Advanced Parkinson'sCompletedNCT00331149Phase 3